The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of osimertinib (Osi) vs. afatinib or erlotinib in patients with classical vs. atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
 
Adam Barsouk
No Relationships to Disclose
 
Omar Elghawy
No Relationships to Disclose
 
Alec Heidlauf
No Relationships to Disclose
 
Connie Yu
No Relationships to Disclose
 
David Yang
No Relationships to Disclose
 
Martin Kurian
No Relationships to Disclose
 
Keshav Goel
No Relationships to Disclose
 
Lynn Rushkin
No Relationships to Disclose
 
Anran Huang
No Relationships to Disclose
 
Teja Voruganti
No Relationships to Disclose
 
Lova Sun
Consulting or Advisory Role - Bayer; Genmab/Seagen; Genzyme; MJH Life Sciences; Regeneron
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); Erasca, Inc (Inst); Immunocore (Inst); IO Biotech (Inst); Seagen (Inst)
 
Aditi Puri Singh
Consulting or Advisory Role - Precision HEOR (I)
Research Funding - Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst)
 
Roger B. Cohen
Consulting or Advisory Role - Actuate Therapeutics; Coherus Biosciences; Fstar Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); F-Star Biotechnology (Inst); Innate Pharma (Inst); Macrogenics (Inst); Xencor (Inst)
 
Charu Aggarwal
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novocure; Pfizer; Sanofi/Regeneron; Takeda
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I)
Research Funding - AstraZeneca/MedImmune (Inst); Candel Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Loxo@Lilly (Inst); Merck Sharp & Dohme (Inst)
 
Melina Elpi Marmarelis
Stock and Other Ownership Interests - Johnson & Johnson; Merck
Honoraria - AstraZeneca; Blueprint Medicines; Janssen Oncology; Novocure; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb/Celgene; Ikena Oncology; Janssen Oncology; Regeneron
Research Funding - AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Regeneron
 
Corey J. Langer
Honoraria - AstraZeneca; Genentech/Roche; Lilly/ImClone; Merck; Takeda Science Foundation
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda
Research Funding - Advantagene (Inst); Amgen; Ariad (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly; Merck (Inst); Stem CentRx (Inst); Trizell (Inst)
Other Relationship - Amgen; Lilly; OncoCyte; Peregrine Pharmaceuticals; Summit Therapeutics; Synta